Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from
Tags :Karina Tschon
kooky, a brand of Zurich-based CEBS, focuses on developing alternative solutions for disposable tableware, has secured an addition EURO 6 million for expansion to Germany and Austria. Early-stage venture capital fund, UVC Partners acted as main
Memo Therapeutics, specialists in the field of antibody discovery and development, has closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination
Alloy Therapeutics, a Boston based biotechnology ecosystem company, has entered into a definitive agreement to acquire deepCDR Biologics, a privately held Basel based developer of deep learning technology for antibody discovery and optimisation. Alloy will
GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round. GlycoEra’s
Walder Wyss advises Perconex Holding in the acquisition of Flex Suisse, an alternative legal service provider in Switzerland and Liechtenstein. The merger creates a talent pool of over 3,000 lawyers, covering three countries with contacts in
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Private investment company Drs Investment sells 100 per cent of the shares in the Swiss software company Xelog to Prologistik Holding. The acquisition of Xelog, the Swiss logistics software specialist, is part of Prologistik’s strategy
Walder Wyss acted as legal counsel to Alentis Therapeutics on the USD 67 million series B financing round. Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors Biomed Partners, BB Pureos
Oculis has closed an oversubscribed USD 57m Series C financing round. It was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay